Lonza loads up $5.5bn funding for Capsugel buy
Swiss pharmaceutical and biotech ingredients supplier Lonza has secured $5.5bn in funds from Bank of America Merrill Lynch and UBS for the acquisition of US dosage form maker Capsugel, in a financing package that includes a variety of debt and equity products.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts